Oragenics Inc (OGEN)

0.35
0.03 9.10
AMEX : Health Care
Prev Close 0.32
Open 0.35
Day Low/High 0.32 / 0.37
52 Wk Low/High 0.50 / 3.87
Volume 105.33K
Avg Volume 37.00K
Exchange AMEX
Shares Outstanding 49.27M
Market Cap 15.28M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oragenics Announces Completion Of Second Closing Of $3.0 Million Preferred Stock Private Placement

Oragenics Announces Completion Of Second Closing Of $3.0 Million Preferred Stock Private Placement

Oragenics, Inc. (NYSE MKT:OGEN), a clinical stage biotechnology company, today announced that it has completed the second closing contemplated by the previously disclosed securities purchase agreement with three accredited...

Oragenics, Inc. Announces Notification Of Noncompliance With Additional NYSE MKT Continued Listing Standard

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT: OGEN) (the "Company") today announced receipt of notification from the NYSE MKT LLC (the "Exchange") that the Company is not in compliance with the...

Oragenics Presents Development Of Novel Lantibiotic Against Clostridium Difficile At The ICAAC Conference

Oragenics, Inc. (NYSE MKT:OGEN), a leader in the development of new antibiotics against infectious diseases and developing effective treatments for oral mucositis, today announced a poster presentation at the joint American...

Oragenics Announces $3.0 Million Preferred Stock Private Placement And $2.4 Million Loan

Oragenics, Inc. (NYSE MKT: OGEN), a clinical stage biotechnology company, today announced that it has entered into a securities purchase agreement with three accredited investors, to purchase up to $3.

Oragenics Provides First Quarter 2017 Update

Oragenics, Inc. (NYSEMKT:OGEN.

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Oragenics, Inc. (NYSE:MKT - OGEN.

Oragenics Shareholder Update

Oragenics Shareholder Update

Oragenics, Inc. (NYSE MKT:OGEN.

Oragenics Presents Engineering Of Improved Lantibiotic Variants At American Society For Microbiology (ASM) Conference On Antibacterial Development

Oragenics Presents Engineering Of Improved Lantibiotic Variants At American Society For Microbiology (ASM) Conference On Antibacterial Development

Oragenics (NYSE MKT:OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it presented at the American Society for...

U.S. FDA Grants Fast Track Designation For The Development Of Oragenics' AG013 For Oral Mucositis

U.S. FDA Grants Fast Track Designation For The Development Of Oragenics' AG013 For Oral Mucositis

Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM), today announced that the U.

Oragenics Receives Supportive FDA Feedback For Initiating A Phase 2 Study Protocol For Oral Mucositis Treatment

Oragenics Receives Supportive FDA Feedback For Initiating A Phase 2 Study Protocol For Oral Mucositis Treatment

Oragenics (NYSE MKT: OGEN.BC), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis (OM) today announced that it has received feedback from the...

Oragenics Selects New Lantibiotic For Further Development In Clostridium Difficile Infections

Oragenics Selects New Lantibiotic For Further Development In Clostridium Difficile Infections

Oragenics (NYSE:MKT - OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced selection of a second generation...

Oragenics, Inc. Announces NYSE MKT Acceptance Of Its Plan Of Compliance

Oragenics, Inc. Announces NYSE MKT Acceptance Of Its Plan Of Compliance

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE MKT:OGEN) (the "Company") today announced that NYSE Regulation has accepted the Company's plan to regain compliance with the NYSE MKT exchange's...

Oragenics Announces Closing Of $4.667 Million Private Placement

Oragenics Announces Closing Of $4.667 Million Private Placement

Oragenics, Inc. (NYSE MKT: OGEN.

Oragenics Announces Completion Of Sale Of Consumer Probiotic Business

Oragenics Announces Completion Of Sale Of Consumer Probiotic Business

Oragenics, Inc. (NYSE MKT: OGEN.

Oragenics Announces Entry Into Definitive Agreement To Sell Consumer Probiotic Business

Oragenics Announces Entry Into Definitive Agreement To Sell Consumer Probiotic Business

Oragenics, Inc. (NYSE MKT: OGEN), a leader in the development of novel antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it has entered into a definitive...

Oragenics, Inc. Announces Notification Of Noncompliance With NYSE MKT Continued Listing Standards

Oragenics, Inc. Announces Notification Of Noncompliance With NYSE MKT Continued Listing Standards

Florida-based biopharmaceutical company  Oragenics, Inc.

Oragenics Announces Positive Results From Confirmatory Animal Study Of AG013 For Treatment Of Oral Mucositis And Plans To Finalize Phase 2 Clinical Trial Protocol

Oragenics Announces Positive Results From Confirmatory Animal Study Of AG013 For Treatment Of Oral Mucositis And Plans To Finalize Phase 2 Clinical Trial Protocol

Oragenics, Inc. (NYSE MKT: OGEN) today announced positive results from a confirmatory animal study supporting previous findings of a Phase 1b clinical trial for the prevention and treatment of oral mucositis (OM).

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Oragenics, Inc. Receives Audit Opinion With Going Concern Explanation

Florida-based biopharmaceutical company  Oragenics, Inc.

Oragenics Receives New Patent For Improved Replacement Therapy For Dental Caries

Oragenics Receives New Patent For Improved Replacement Therapy For Dental Caries

Florida-based biopharmaceutical company  Oragenics, Inc.

Oragenics Announces Successful Completion Of Pre-IND Meeting For OG253

Oragenics Announces Successful Completion Of Pre-IND Meeting For OG253

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT - OGEN) has announced today that it met representatives of the Food and Drug Administration ("FDA") in a Pre-IND meeting concerning its lead lantibiotic...

8 Stocks Under $10 Making Big Moves Higher

8 Stocks Under $10 Making Big Moves Higher

These under-$10 stocks look poised to move even higher from current levels.

Oragenics Reports Positive Results Of An Independent ProBiora3 Study

Oragenics Reports Positive Results Of An Independent ProBiora3 Study

Oragenics, Inc. (NYSE MKT:OGEN) announced today the successful completion of an independent study evaluating the effects of a chewable tablet containing ProBiora3®, in early childhood development of dental caries in...

Oragenics (OGEN) Is Today's Strong On High Volume Stock

Oragenics (OGEN) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Oragenics (OGEN) as a strong on high relative volume candidate

Oragenics Reports Positive In Vivo Antibiotic Efficacy Data In Critical Animal Study

Oragenics Reports Positive In Vivo Antibiotic Efficacy Data In Critical Animal Study

Oragenics, Inc. (NYSE MKT: OGEN) and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, announced today positive data on multiple compounds from Oragenics' Mutacin 1140 ("MU1140") lantibiotic platform...

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Oragenics Shareholders Re-elect Existing Board Of Directors; Approve And Ratify Other Proposals

Oragenics Shareholders Re-elect Existing Board Of Directors; Approve And Ratify Other Proposals

Florida-based biopharmaceutical company Oragenics, Inc. (NYSE MKT: OGEN) has announced today that, based on proxies submitted to the independent Inspector of Election for its 2015 Annual Meeting of Shareholders, results...